AbbVie cuts Q3 adjusted diluted EPS outlook to $3.73-$3.77 after $216 million acquired IPR&D, milestones expense
ABBV•AbbVie lowered its Q3 2026 adjusted diluted EPS outlook to $3.73-$3.77 from $3.84-$3.88, citing $216 million in acquired IPR&D and milestones expense, a $0.11-per-share impact. It also reduced its full-year outlook to $13.76-$13.96 and raised its expense estimate to $1.25 billion from $1.04 billion.
1. Outlook lowered
AbbVie cut its Q3 2026 adjusted diluted EPS guidance to $3.73-$3.77 from $3.84-$3.88, reflecting $216 million in acquired IPR&D and milestones expense, equal to a $0.11-per-share impact. Full-year 2026 adjusted diluted EPS guidance fell to $13.76-$13.96 from $13.87-$14.07 on the same per-share impact; the company raised its full-year expense expectation to $1.25 billion from $1.04 billion.
